Neonatal ECMO Study of Temperature (NEST)--a randomised controlled trial.
BACKGROUND
Existing evidence indicates that once mature neonates with severe cardio-respiratory failure become eligible for Extra Corporeal Membrane Oxygenation (ECMO) their chances of intact survival are doubled if they actually receive ECMO. However, significant numbers survive with disability. NEST is a multi-centre randomised controlled trial designed to test whether, in neonates requiring ECMO, cooling to 34 degrees C for the first 48 to 72 hours of their ECMO course leads to improved later health status. Infants allocated to the control group will receive ECMO at 37 degrees C throughout their course, which is currently standard practice around the world. Health status of both groups will be assessed formally at 2 years corrected age.


METHODS
All infants recruited to the study will be cared for in one of the four United Kingdom (UK) ECMO centres. Babies who are thought to be eligible will be assessed by the treating clinician who will confirm eligibility, ensure that consent has been obtained and then randomise the baby using a web based system, based at the National Perinatal Epidemiology Unit (NPEU) Clinical Trials Unit. Trial registration.Babies allocated ECMO without cooling will receive ECMO at 37 degrees C +/- 0.2 degrees C. Babies allocated ECMO with cooling will be managed at 34 degrees C +/- 0.2 degrees C for up to 72 hours from the start of their ECMO run. The minimum duration of cooling will be 48 hours. Rewarming (to 37 degrees C) will occur at a rate of no more than 0.5 degrees C per hour. All other aspects of ECMO management will be identical.


METHODS
Cognitive score from the Bayley Scales of Infant and Toddler Development, 3rd edition (Bayley-III) at age of 2 years (24 - 27 months).


CONCLUSIONS
For the primary analysis, children will be analysed in the groups to which they are assigned, comparing the outcome of all babies allocated to "ECMO with cooling" with all those allocated to "ECMO" alone, regardless of deviation from the protocol or treatment received. For the primary outcome the analysis will compare the mean scores for each group of surviving babies. The rationale for this choice of primary analysis is to give a fair representation of the average ability of assessable children, accepting the limitation that excluding deaths might impose.The consistency of the effect of cooling on the group of babies recruited to the trial will be explored to see whether cooling is of particular help, or not, to specific subgroups of infants, using the statistical test of interaction. Therefore pre-specified subgroup analyses include: (i) whether the ECMO is veno-arterial or veno-venous; (ii) whether the child's oxygenation index at the time of recruitment is <60 or > or = 60; (iii) initial aEEG pattern shown on the cerebral function monitor, and (iv) primary diagnostic group.


BACKGROUND
Current Controlled Trials ISRCTN72635512.
Field
David J
DJ
Department of Heath Science, Department of Health Sciences, University of Leicester, 22-28 Princess Road West, Leicester, UK. df63@le.ac.uk
Firmin
Richard
R
Azzopardi
Denis V
DV
Cowan
Frances
F
Juszczak
Edmund
E
Brocklehurst
Peter
P
D001831:Body Temperature; D002658:Developmental Disabilities / Q000453:epidemiology / Q000209:etiology / Q000517:prevention & control*; D015199:Extracorporeal Membrane Oxygenation / Q000379:methods*; D005260:Female; D005500:Follow-Up Studies; D006333:Heart Failure / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D006801:Humans; D007036:Hypothermia, Induced / Q000379:methods*; D007231:Infant, Newborn; D007360:Intelligence; D008297:Male; D012131:Respiratory Insufficiency / Q000150:complications / Q000503:physiopathology / Q000628:therapy*; D013997:Time Factors; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology
J Clin Invest. 1997 Jan 15;99(2):248-56
9005993
J Pediatr. 1999 Aug;135(2 Pt 1):153-61
10431108
Pediatr Res. 1998 Sep;44(3):304-11
9727705
Pediatrics. 2000 Oct;106(4):684-94
11015509
J Neurosci. 1995 Nov;15(11):7250-60
7472479
Arch Dis Child Fetal Neonatal Ed. 2003 Mar;88(2):F128-33
12598502
Lancet. 1996 Jul 13;348(9020):75-82
8676720
Pediatr Neurol. 1995 May;12(4):294-304
7546003
Anesth Analg. 2003 Apr;96(4):1209-1213
12651686
N Engl J Med. 2002 Feb 21;346(8):549-56
11856793
Semin Neonatol. 2000 May;5(2):127-40
10859707
Pediatr Res. 2008 Aug;64(2):183-8
18391842
Dev Med Child Neurol. 2004 Jun;46(6):389-97
15174530
Eur J Paediatr Neurol. 1999;3(6):255-63
10595670
Ann Thorac Surg. 1996 Jul;62(1):130-5
8678631
Neurology. 2002 Aug 13;59(3):438-40
12177381
J Pediatr. 2004 Mar;144(3):301-8
15001932
N Engl J Med. 2005 Oct 13;353(15):1574-84
16221780
J Pediatr Surg. 1994 Feb;29(2):186-90; discussion 190-1
8176589
J Pediatr. 2001 Mar;138(3):332-7
11241038
Pediatrics. 2004 Jan;113(1 Pt 1):95-100
14702455
Pediatrics. 2000 Jul;106(1 Pt 1):92-9
10878155
Pediatrics. 2005 Oct;116(4):1001-6
16199715
Dev Med Child Neurol. 2008 Jan;50(1):58-62
18173632
Arch Pediatr Adolesc Med. 2004 Feb;158(2):178-82
14757610
Circulation. 1995 Nov 1;92(9 Suppl):II334-40
7586434
Dev Med Child Neurol. 2006 Jun;48(6):424-8
16700931
J Pediatr. 2004 Feb;144(2):223-8
14760266
Pediatr Res. 1995 May;37(5):667-70
7603788
N Engl J Med. 2000 Aug 10;343(6):378-84
10933736
Pediatr Res. 1996 Apr;39(4 Pt 1):591-7
8848330
J Pediatr. 2004 Mar;144(3):309-15
15001933
J Pediatr Psychol. 2004 Mar;29(2):143-55
15096535
Lancet. 2005 Feb 19-25;365(9460):663-70
15721471
Pediatr Res. 2002 Jan;51(1):13-9
11756634
Pediatrics. 1998 Oct;102(4 Pt 1):885-92
9755260
Lancet. 2001 Apr 7;357(9262):1094-6
11297963
Acta Paediatr. 2001 Nov;90(11):1288-91
11808901
Pediatrics. 2000 Aug;106(2 Pt 1):235-43
10920145
Child Dev. 1985 Oct;56(5):1314-25
4053745